November 28, 2012
Amarin is still in a holding pattern, waiting for an FDA ruling on its key drug Vascepa's NCE status, but that didn't stop Citigroup from initiating coverage with a buy recommendation and a $20 price target that is a near double from where shares sit today. Watch as Motley Fool health-care analyst David Williamson discusses why Citi likes Amarin so much and whether he agrees with that assessment.
The biotech space can make or break investors overnight, and while Amarin might not disappear into thin air, the success of its new triglyceride-lowering drug is key to the company's future success or failure. The company has huge potential, but don't invest a dollar before reading everything you need to know about Amarin. You can start now with top Fool.com analyst Max Macaluso's premium research report. Click here now to keep reading.